Titre : Fibrillines

Fibrillines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Controlled Substances
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Fibrillines : Questions médicales les plus fréquentes", "headline": "Fibrillines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Fibrillines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-24", "dateModified": "2025-04-19", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Fibrillines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines de la matrice extracellulaire", "url": "https://questionsmedicales.fr/mesh/D016326", "about": { "@type": "MedicalCondition", "name": "Protéines de la matrice extracellulaire", "code": { "@type": "MedicalCode", "code": "D016326", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.860.300" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Fibrilline-1", "alternateName": "Fibrillin-1", "url": "https://questionsmedicales.fr/mesh/D000071838", "about": { "@type": "MedicalCondition", "name": "Fibrilline-1", "code": { "@type": "MedicalCode", "code": "D000071838", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.860.300.400.500" } } }, { "@type": "MedicalWebPage", "name": "Fibrilline-2", "alternateName": "Fibrillin-2", "url": "https://questionsmedicales.fr/mesh/D000071840", "about": { "@type": "MedicalCondition", "name": "Fibrilline-2", "code": { "@type": "MedicalCode", "code": "D000071840", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.860.300.400.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Fibrillines", "alternateName": "Fibrillins", "code": { "@type": "MedicalCode", "code": "D000071837", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Dieter P Reinhardt", "url": "https://questionsmedicales.fr/author/Dieter%20P%20Reinhardt", "affiliation": { "@type": "Organization", "name": "Faculty of Medicine, Department of Anatomy and Cell Biology, McGill University, Montreal, Canada. dieter.reinhardt@mcgill.ca." } }, { "@type": "Person", "name": "Clair Baldock", "url": "https://questionsmedicales.fr/author/Clair%20Baldock", "affiliation": { "@type": "Organization", "name": "Division of Cell-Matrix Biology and Regenerative Medicine, Wellcome Centre for Cell-Matrix Research, The University of Manchester, Manchester, UK." } }, { "@type": "Person", "name": "Gerhard Sengle", "url": "https://questionsmedicales.fr/author/Gerhard%20Sengle", "affiliation": { "@type": "Organization", "name": "Center for Biochemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Department of Pediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Cologne Center for Musculoskeletal Biomechanics (CCMB), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany." } }, { "@type": "Person", "name": "Stuart A Cain", "url": "https://questionsmedicales.fr/author/Stuart%20A%20Cain", "affiliation": { "@type": "Organization", "name": "Division of Cell-Matrix Biology and Regenerative Medicine, Wellcome Centre for Cell-Matrix Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom." } }, { "@type": "Person", "name": "Muthu L Muthu", "url": "https://questionsmedicales.fr/author/Muthu%20L%20Muthu", "affiliation": { "@type": "Organization", "name": "Faculty of Medicine, Department of Anatomy and Cell Biology, McGill University, Montreal, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Impact of an enterprise controlled substance management system on labor and inventory costs.", "datePublished": "2024-10-26", "url": "https://questionsmedicales.fr/article/39460665", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/ajhp/zxae305" } }, { "@type": "ScholarlyArticle", "name": "ParalichenysinDY4, a novel bacteriocin-like substance, is employed to control Clostridium perfringens.", "datePublished": "2024-09-06", "url": "https://questionsmedicales.fr/article/39245094", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ijbiomac.2024.135412" } }, { "@type": "ScholarlyArticle", "name": "Childhood exposure to per- and polyfluoroalkyl substances and neurodevelopment in the CHARGE case-control study.", "datePublished": "2022-09-13", "url": "https://questionsmedicales.fr/article/36108719", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.envres.2022.114322" } }, { "@type": "ScholarlyArticle", "name": "Structural instability and linear allocation control in generalized models of substance use disorder.", "datePublished": "2024-03-02", "url": "https://questionsmedicales.fr/article/38438105", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.mbs.2024.109169" } }, { "@type": "ScholarlyArticle", "name": "Comparison of controlled drugs and new psychoactive substances (NPS) regulations in East and Southeast Asia.", "datePublished": "2023-01-12", "url": "https://questionsmedicales.fr/article/36642324", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.yrtph.2023.105338" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Scléroprotéines", "item": "https://questionsmedicales.fr/mesh/D012596" }, { "@type": "ListItem", "position": 5, "name": "Protéines de la matrice extracellulaire", "item": "https://questionsmedicales.fr/mesh/D016326" }, { "@type": "ListItem", "position": 6, "name": "Fibrillines", "item": "https://questionsmedicales.fr/mesh/D000071837" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Fibrillines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Fibrillines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Fibrillines", "description": "Comment diagnostiquer une déficience en fibrilline ?\nQuels examens sont utilisés pour évaluer les fibrillines ?\nLes tests génétiques sont-ils fiables pour les fibrillines ?\nQuels symptômes indiquent un problème de fibrilline ?\nPeut-on détecter des anomalies fibrillaires par imagerie ?", "url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Fibrillines", "description": "Quels sont les symptômes d'une maladie liée aux fibrillines ?\nLes douleurs articulaires sont-elles liées aux fibrillines ?\nY a-t-il des signes cutanés associés aux fibrillines ?\nLes problèmes oculaires sont-ils fréquents avec les fibrillines ?\nComment les anomalies cardiovasculaires se manifestent-elles ?", "url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Fibrillines", "description": "Peut-on prévenir les maladies liées aux fibrillines ?\nY a-t-il des conseils de mode de vie pour les patients fibrillaires ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nComment le suivi médical aide-t-il les patients ?\nLes activités physiques sont-elles sûres pour les patients ?", "url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Fibrillines", "description": "Quels traitements existent pour les troubles des fibrillines ?\nLa chirurgie est-elle nécessaire pour les problèmes de fibrillines ?\nDes médicaments peuvent-ils aider les patients fibrillaires ?\nY a-t-il des thérapies spécifiques pour les fibrillines ?\nComment gérer les douleurs liées aux fibrillines ?", "url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Fibrillines", "description": "Quelles sont les complications possibles des troubles fibrillaires ?\nLes complications cardiovasculaires sont-elles fréquentes ?\nComment prévenir les complications liées aux fibrillines ?\nLes douleurs chroniques sont-elles une complication courante ?\nLes problèmes respiratoires peuvent-ils être liés aux fibrillines ?", "url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Fibrillines", "description": "Quels sont les facteurs de risque pour les troubles des fibrillines ?\nLes antécédents familiaux augmentent-ils le risque ?\nLes mutations génétiques sont-elles un facteur de risque ?\nLes conditions médicales préexistantes influencent-elles le risque ?\nL'âge est-il un facteur de risque pour les troubles fibrillaires ?", "url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en fibrilline ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic se fait par des tests génétiques et des examens cliniques." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer les fibrillines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'échographie, l'IRM et les tests sanguins peuvent être utilisés." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils fiables pour les fibrillines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques sont très fiables pour identifier les mutations des fibrillines." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème de fibrilline ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des douleurs articulaires et des anomalies cardiovasculaires peuvent indiquer un problème." } }, { "@type": "Question", "name": "Peut-on détecter des anomalies fibrillaires par imagerie ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'imagerie peut révéler des anomalies dans les tissus conjonctifs." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une maladie liée aux fibrillines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs articulaires, des problèmes cardiaques et des anomalies oculaires." } }, { "@type": "Question", "name": "Les douleurs articulaires sont-elles liées aux fibrillines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs articulaires peuvent être un signe de dysfonctionnement des fibrillines." } }, { "@type": "Question", "name": "Y a-t-il des signes cutanés associés aux fibrillines ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes cutanés comme des vergetures peuvent être observés en cas de déficience en fibrilline." } }, { "@type": "Question", "name": "Les problèmes oculaires sont-ils fréquents avec les fibrillines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des problèmes comme le décollement de la rétine peuvent survenir." } }, { "@type": "Question", "name": "Comment les anomalies cardiovasculaires se manifestent-elles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent se manifester par des dilatations aortiques ou des ruptures vasculaires." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées aux fibrillines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un suivi médical régulier peut aider à détecter les problèmes tôt." } }, { "@type": "Question", "name": "Y a-t-il des conseils de mode de vie pour les patients fibrillaires ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est recommandé." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils aider à la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les personnes à risque et permettre une surveillance précoce." } }, { "@type": "Question", "name": "Comment le suivi médical aide-t-il les patients ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le suivi médical permet de surveiller l'évolution de la maladie et d'ajuster les traitements." } }, { "@type": "Question", "name": "Les activités physiques sont-elles sûres pour les patients ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des activités physiques modérées sont généralement sûres, mais doivent être adaptées à chaque patient." } }, { "@type": "Question", "name": "Quels traitements existent pour les troubles des fibrillines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la surveillance, la chirurgie et des médicaments pour gérer les symptômes." } }, { "@type": "Question", "name": "La chirurgie est-elle nécessaire pour les problèmes de fibrillines ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie peut être nécessaire pour corriger des anomalies cardiovasculaires graves." } }, { "@type": "Question", "name": "Des médicaments peuvent-ils aider les patients fibrillaires ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments peuvent aider à gérer les symptômes et à prévenir les complications." } }, { "@type": "Question", "name": "Y a-t-il des thérapies spécifiques pour les fibrillines ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de thérapie spécifique, mais des soins symptomatiques sont offerts." } }, { "@type": "Question", "name": "Comment gérer les douleurs liées aux fibrillines ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La gestion de la douleur peut inclure des analgésiques et des thérapies physiques." } }, { "@type": "Question", "name": "Quelles sont les complications possibles des troubles fibrillaires ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des ruptures vasculaires, des problèmes cardiaques et des douleurs chroniques." } }, { "@type": "Question", "name": "Les complications cardiovasculaires sont-elles fréquentes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications cardiovasculaires sont courantes et peuvent être graves." } }, { "@type": "Question", "name": "Comment prévenir les complications liées aux fibrillines ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier et un traitement approprié peuvent aider à prévenir les complications." } }, { "@type": "Question", "name": "Les douleurs chroniques sont-elles une complication courante ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les douleurs chroniques peuvent survenir et nécessitent une gestion adéquate." } }, { "@type": "Question", "name": "Les problèmes respiratoires peuvent-ils être liés aux fibrillines ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des problèmes respiratoires peuvent survenir en raison de complications pulmonaires." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles des fibrillines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des conditions médicales." } }, { "@type": "Question", "name": "Les antécédents familiaux augmentent-ils le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un historique familial de troubles fibrillaires augmente le risque de développer la maladie." } }, { "@type": "Question", "name": "Les mutations génétiques sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines mutations génétiques sont directement liées aux troubles des fibrillines." } }, { "@type": "Question", "name": "Les conditions médicales préexistantes influencent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conditions comme le syndrome de Marfan augmentent le risque de complications." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour les troubles fibrillaires ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'âge peut influencer la gravité des symptômes, mais n'est pas un facteur de risque direct." } } ] } ] }

Sources (10000 au total)

Impact of an enterprise controlled substance management system on labor and inventory costs.

In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are post... To evaluate the impact of an enterprise controlled substance (ECS) management system with integration of analytics software on labor requirements and inventory cost within a health-system pharmacy.... A prospective, pre-post observational study was designed to assess the impact of implementing a solution that connects disparate systems with the integration of analytics software. Three study modules... Both of the study facilities had a decrease in CS daily stockouts and an increase in inventory turns compared to baseline, while the total number of transactions (vends) at the central vault and decen... An inventory management system integrated with an advanced analytics tool provided a reduction in the time spent on receiving, storing, and reconciling CS records while the number of transactions incr...

Childhood exposure to per- and polyfluoroalkyl substances and neurodevelopment in the CHARGE case-control study.

Per- and polyfluoroalkyl substances (PFAS) are shown to have neurotoxic effects on animals, but epidemiological evidence for associations between childhood PFAS exposure and neurodevelopment is inconc... We included 551 children 2-5 years old from the CHildhood Autism Risks from Genetics and Environment (CHARGE) case-control study. Children were clinically diagnosed and classified as having ASD, DD, O... Childhood perfluorooctanoic acid (PFOA) was associated with increased odds of ASD (odds ratio [OR] per ln ng/mL increase: 1.99, 95% confidence interval [CI]: 1.20, 3.29) and DD (OR: 2.16, 95% CI: 1.21... In this case-control study, childhood PFOA, PFHpA, and a PFAS mixture was associated with increased odds of ASD, while PFUnDA was associated with decreased odds of ASD. Because we used concurrent meas...

Association between exposure to perfluoroalkyl substances (PFAS) and endometriosis in the ENDEA case-control study.

Perfluoroalkyl substances (PFAS) are environmental contaminants present in a wide range of consumer products and frequently detected in drinking water. They have been linked to adverse reproductive he... To explore the association between plasma concentrations of several PFAS, considered individually and as a mixture, and the risk of endometriosis in women of childbearing age.... Between 2018 and 2020, 42 patients with endometriosis and 90 controls undergoing abdominal surgery were recruited at two public hospitals in Granada, Spain. The presence or absence of endometriosis wa... In models adjusted for age, schooling, and parity, perfluorotridecanoic acid (PFTrDA) was associated with higher odds of endometriosis (odds ratio [OR] = 1.74; 95 % CI = 1.11-2.73 per 2-fold increase ... These findings suggest that exposure to certain PFAS may increase the odds of endometriosis. However, given the modest sample size, further studies are warranted to verify these results....